Financial Results for the First Half Ended September 30, 2025

TAKARA BIO INC.

November 13, 2025

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Content

Consolidated Financial Results for the First Half Ended September 30, 2025

(¥m)	FY2026 First Half	Y/Y	Comparison with May 13 forecast
Net sales	18,794	▲963 ▲4.9%	▲2,505 ▲11.8%
Gross profit	10,564	▲1,880 ▲15.1%	▲1,820 ▲14.7%
SG&A expense	12,907	+878 +7.3%	▲927 ▲6.7%
Operating profit	▲2,342	▲2,759 -	▲892 -
R&D expenses	3,497	+15 +0.4%	▲59 ▲1.7%

Factors behind changes in Operating profit (¥m)
(Year on year comparison)

Lower unit sales volume	▲365
Difference in sales composition	▲1,232
Effects of foreign exchange rate fluctuations	▲283
Decrease in gross profit	**▲1,880**
Increase in R&D expenses	▲15
Increase in other expenses	▲665
Effects of foreign exchange rate fluctuations	▲198
Increase in SG&A	**▲878**
Decrease in Operating profit	**▲2,579**

¥m: millions of yen FY2026: from Apr. 1, 2025 to Mar. 31, 2026

Consolidated Financial Results for the First Half Ended September 30, 2025 : Sales by Business Group

(¥m)	Net sales	Y/Y	Comparison with May 13 forecast
Reagents	14,272	▲1,133 ▲7.4%	▲1,746 ▲10.9%
Instruments	402	▲23 ▲5.6%	▲292 ▲42.1%
CDMO	2,546	+271 +12.0%	▲477 ▲15.8%
Regenerative medicine	1,622	+658 +68.3%	+6 +0.4%
Gene analysis / testing & others	923	▲386 ▲29.5%	▲483 ▲34.4%
Gene Therapy	1,573	▲78 ▲4.7%	+10 +0.7%

Y/Y change

Reagents: Amid the ongoing global downturn in the life sciences research market, sales declined due to factors including reduced U.S. government research funding and the economic slowdown in China.

Instruments: Sales of PCR related instruments (Japan) and single cell analysis systems (U.S.) decreased.

Regenerative medicine products: Sales increased driven by vector manufacturing contracts and quality testing contracts.

Gene analysis/ testing: Sales declined due to weak demand from large-scale projects and a significant drop in genome analysis service orders

Gene Therapy: AM Products (mRNA Vaccine-Related) grew, but overall sales declined due to lower sales of RetroNectin®.

*AM: Ancillary Materials

Consolidated Financial Results for the First Half Ended September 30, 2025: Sales of Reagents by Region

(¥m)	FY2026 First Half	Comparison with May 13 forecast		
		Change	For exchange	Ratio (Exchange excluded)
Japan	2,771	+73	-	+2.7%
U.S.	6,844	+63	▲182	+3.6%
Europe	1,756	+110	▲23	+8.1%
China	1,927	▲1,386	▲58	▲40.1%
Korea	572	▲22	▲46	+4.1%
India	398	+27	▲25	+14.3%
Total	14,272	▲1,133	▲335	▲5.2%

Comparison with initial forecast† (local currency basis)

<Japan> With limited market growth primarily in academia, sales of research reagents remained stagnant, while increased sales were driven by testing kits.

<U.S.> While basic research remains sluggish due to the impact of government policies, B2B sales have increased. Despite rising inquiries for Spatial products, order volumes have not increased accordingly.

<Europe> Sales of OEM/Customized Products are favorable.

<China> Both Research-use/Catalog products and OEM/Customized products showed subdued performance, primarily due to intensified competition and inventory adjustments following changes in the distributor network.

<Korea> Refrain from purchasing due to the effect of the delay in the payment of the government's research budget.

<India> Sales increased due to higher sales of NGS-related reagents.

Content

REAGENT BUSINESS

Reagents Business (U.S.)

(USD M)

Sales in the U.S.



Issues & Measures

- Costs related to the acquired Curio Bioscience Inc.: To be absorbed through expanded sales of Spatial-related products and synergies with existing NGS (Next Generation Sequencing) products.
- Minimizing the impact of government R&D budget cuts: Further shift toward B2B to mitigate the effect.
- Government additional tariff policy: Avoided by expanding manufacturing in Japan.

Full-Year Status

- The impact of government budget cuts is expected to remain significant, potentially slowing the expansion of spatial product sales.
- Since October, government budgets have yet to pass through parliament, and if this situation continues, the resulting shutdown of government agencies could severely affect sales.
- Although some decline in venture activity is anticipated, B2B business is expected to remain solid.
- The impact of tariffs is projected to be kept to a minimum.

Regarding the Acquisition of Curio Bioscience

Trends in the Number of Academic Papers



- In the fiscal year ending March 31, 2026, approximately ¥2 billion increase in expenses expected due to the acquisition
- Spatial analysis is expected to continue as a key trend within NGS, following transcriptomics and single-cell analysis. It is a field with strong growth potential, The technology acquired through the acquisition of Curio Biosciences Inc. is capable of supporting multi-platform and multi-omics applications.
- Although the Company had anticipated expanding sales of new spatial products through its group's global distribution network, primarily in the U.S., however, the downturn in the research market—driven by reductions in U.S. research grants—has been more severe than expected. As a result, sales of spatial products are anticipated to fall short, with an estimated achievement rate of 30% against the group's sales target of ¥2 billion.

Minimizing the Impact of Mutual Tariffs : Establishing a Multipolar Global Manufacturing System and Minimizing the impact

Europe (Goteborg)
- Manufacturing a portion of products for the U.S. market
- Expanding the manufacturing of OEM/Customized products used in Europe

U.S. (San Jose)
- Shift manufacturing of products for Chinese market to Japan
- Expanding the manufacturing of OEM/Customized products for the U.S.

China (Dalian)
- Reduce production of export-bound products and shift to manufacturing raw materials
- Expanding the product development and manufacturing for domestic market

Japan (Kusatsu)
- Expanding the manufacturing of raw materials and products for the U.S. and Japan.
- Manufacturing products for Chinese market previously manufactured in the U.S.

Significantly expanded manufacturing in Japan and completed the transition. Limited the financial impact to approximately 300 million yen for this fiscal year.
From next fiscal year onward, the Company aims to leverage the established framework to respond flexibly and minimize impact.

Reagents Business (China)



Issues & Measures

- In addition to the shrinking basic research market, Intensifying competition with Chinese companies: Securing market share through restructuring the distributor network and China-specific product development.
- Developing B2B customers: Expanding NGS and Spatial product sales to CROs.

Full-Year Status

- Competitors have been offering significant discounts, and the Company is struggling under the deflationary environment.
- Further disadvantage is anticipated due to delayed response times for custom solutions.
- Although the focus remains on OEM/Customized products leveraging technologically superior products, long negotiation cycles are likely to result in limited contribution.

TaKaRa

Reagents Business (Japan)





Issues & Measures

• Stagnation in sales of general research reagents centered on PCR: Focus on development and expansion of application field (diagnostic segment) products and AM products such as mRNA synthesis enzymes.

•Shift away from academia dependence: Acquire B2B customized /OEM business deals.

•Product line obsolescence: Expand and promote NGS products with spatial new products as the core.

Full-Year Status

• General research reagents are almost flat compared to the previous term.

•Sales in the food poisoning testing segment remain strong, but revenue from newly targeted animal and livestock testing is insufficient.

•Several B2B deals focused on infectious diseases etc, but still small-scale.

•Sales of spatial products fell short of the plan; promote together with contract analysis services.

TaKaRa

Reagents Business (Europe)

(EUR M)

Sales in Europe



Issues & Measures

- Market slowdown due to inflation and geopolitical risks: Generate B2B opportunities through the Business Development team.
- Effective utilization of the Sweden site: Launch manufacturing of PCR enzymes for B2B.
- Expansion of spatial new products: Accelerate early market introduction and maximize synergy through dedicated NGS sales specialists.

Full-Year Status

- Market recovery remains slow, but core NGS product sales show signs of stabilization.
- Multiple negotiations underway for enzymes used in mRNA vaccine manufacturing.
- As part of U.S. tariff countermeasures, the Sweden site is also sharing a portion of the manufacturing.

First Half Second Half

TaKaRa

CDMO BUSINESS

TaKaRa

CDMO Business



Issues & Measures

- Stable operation and efficient management of cell processing and vector manufacturing: Strengthen support for early-stage development projects and reduce dependence on large-scale projects to diversify risk.
- Addressing revenue decline due to intensified competition in genome analysis: Expand high-value new service offerings such as spatial analysis using spatial products and single-cell analysis.

Full Year Status

- Received numerous small- to medium-sized orders from ventures and startups supported by government programs, but workload leveling remains a challenge.
- Stable orders for ViSpot's virus clearance tests and virus safety tests.
- Expansion of business negotiations for spatial analysis services.
- Lost large-scale genome analysis orders due to price mismatch caused by ongoing price reductions.

Recognition of Extraordinary Losses

- An impairment loss of approximately ¥39 billion on large-scale parallel cell processing equipment and virus vector mass culture and purification equipment, expanded under the CDMO business, was recorded as an extraordinary loss.



GCCP 3 (scheduled for completion in 2027)

- Dual-use facility with the role of a vaccine manufacturing site and a material manufacturing site supported by the Ministry of Economy, Trade and Industry.
- Flexible small- and medium-scale manufacturing

Background of Extraordinary Loss & Future Direction

- Although the Company made upfront investments anticipating large-scale manufacturing demand in the fields of regenerative medicine, cell therapy, and gene therapy, the trend has shifted as major pharmaceutical companies have discontinued development.
- With the impact of government venture support, demand for small- to mid-scale (50L level and above) manufacturing of viral vectors and proteins for gene therapy is strong. The focus is shifting from facilities designed for large-scale production to small- and mid-scale manufacturing targeting low-dose/local administration from the early development stage.
- Utilize CGCP Building 1 (small scale) and CGCP Building 3 (medium scale, under construction).

CGCP: Gene and Cell Processing Center

CDMO business: Promote C 'R' DMO strategy
Leverage our unique platform-based technology

Leveraging our experience in clinical development of proprietary platform-based technologies such as Spo-T™, CereAAV™, SonuAAV™ and TBI-1301, the company provides comprehensive support services from the initial development stage (R) to accompany clients with a view to future development (D) and manufacturing (M).

- **Our strengths are that we can provide our clients with experience in proprietary platform technology and clinical development projects to their development seeds**
- **Providing comprehensive support services for clients from the initial development stage in anticipation of future development (D) and manufacturing (M)**

Platform Technology

CereAAV™	SonuAAV™	Spo-T™ method
• Penetration of the Brain-Blood Barrier (BBB) by Intravenal Dosing • Achieved high-efficiency gene introduction to the brains and avoidance of hematotoxicity	• High-efficiency gene transfer into inner ear tissue • Hearing Improvement Confirmed in Hearing Loss Model Mice	• Develops a short-term production method for high-quality • CAR-T cells. Reduces manufacturing costs and improves effectiveness

GENE THERAPY BUSINESS

Gene Therapy Business: Strengthening quality management systems & promoting development of high-value new AM products

Sales of Gene Therapy



Issues & Measures

- Development of AM products following RetroNectin® and lymphocyte culture media: Promotion of marketing and development projects.
- Expand sales of GMP-grade enzymes for mRNA vaccine manufacturing: Collaborate with the Business Development team of overseas subsidiaries.
- Obtain approval for TBI-1301: Early inclusion in clinical trials.

Full Year Status

- Expansion of the mRNA synthesis enzyme lineup （7 High Quality grades and 4 GMP grades available), developing negotiations with pharmaceutical companies.
- Submission of clinical trial protocol for TBI-1301 confirmatory trial.

AM(Ancillary Materials) products: Manufacturing aids for biologics that require GMP compliance, such as aseptic collateral

Gene Therapy Business: Promote the development of TBI-1301, NY-ESO-1・siTCR® gene therapy product

- March 27, 2018 : Designated as a product subject to the MHLW's SAKIGAKE Designation System
- June 17, 2020: Designated as Orphan Regenerative Medicine Products for Synovial Sarcoma
- May 13, 2025: (Initially aimed for conditional approval) Plan changed to conduct confirmatory trials and aim for full approval
- September 16, 2025: Completion of Clinical Trial Notification Process in Japan for Confirmatory Study of NY-ESO-1・siTCR™ Gene Therapy

Overview of Verification Trial

Title	Multicenter Study of TBI-1301 (INN: mipetresgene autoleucel; Mip-cel) for NY-ESO-1 Antigen-Positive Synovial Sarcoma NY-ESO-1
Phase	Phase III
Indication	Unresectable advanced or recurrent synovial sarcoma
Design	Non-controlled, multicenter
Enrollment	5 patients

Clinical Trial Information：

Japanese jRCT No.：jRCT2073250089　English ClinicalTrials.gov No：NCT07174427

Content

- Consolidated Financial Results for the First Half Ended September 30, 2025
- Status of Each Business
- **Consolidated Financial Forecast for the year ending March 31, 2026 (Revised)**

Consolidated Financial Forecast for the year ending March 31, 2026 (Revised)

(¥m)	FY2026 Forecast (Revised)	Y/Y	Comparison with May 13 forecast
Net sales	42,100	▲2,939 ▲6.5%	▲10,400 ▲19.8%
Reagents	29,731	▲2,263 ▲7.1%	▲7,371 ▲19.9%
Instruments	1,081	▲90 ▲7.7%	▲686 ▲38.8%
CDMO	8,245	+132 +1.6%	▲1,958 ▲19.2%
Gene Therapy	3,040	▲717 ▲19.1%	▲383 ▲11.2%

Y/Y change

Reagents: Japan, U.S., Europe, South Korea, and India are expected to show y/y growth, while China is projected to see a significant decline due to the impact of last year's distributor network restructuring, the economic downturn, and intensifying competition with local companies.

Instruments: Sales declined y/y due to a decrease in single-cell analysis system sales and other factors.

Contract Manufacturing for Regenerative Medicine Products: Despite a projected decrease in vector manufacturing contracts, overall sales is expected to grow, driven by increased demand for cell processing and quality testing services.

Contract Services for Genetic Analysis and Testing: Sales are expected to decline due to sluggish movement of large-scale budgets and a decrease in orders for genome analysis services.

Gene Therapy：Sales of AM products are expected to grow, but overall sales are projected to decline due to anticipated reduced demand for RetroNectin®.

Consolidated Financial Forecast for the year ending March 31, 2026 (Revised)

(¥m)	FY2026 Full-Year forecast (Revised)	Y/Y	Comparison with May 13 forecast
Net sales	42,100	▲2,939 ▲6.5%	▲10,400 ▲19.8%
Cost of sales	20,208	+1,236 +6.5%	+2,266 ▲10.1%
Gross profit	21,891	▲4,175 ▲16%	▲8,133 ▲27.1%
SG&A expenses	25,891	+2,087 +8.8%	▲1,633 ▲5.9%
Operating profit	▲4,000	▲6,263 -	▲6,500 -
Ordinary profit	▲4,400	▲6,992 -	▲6,900 -
Net income attributable to owners of parent	▲9,000	▲10,041 -	▲10,300 -

SG&A expenses:

Expenses related to the acquisition of Curio Bioscience Inc. and goodwill amortization are within expectations. By reviewing personnel structure, prioritizing and focusing R&D, and striving to reduce administrative costs, the projected amount is ¥25,891 million.

Operating profit:

Expenses Estimated at ▲¥4,000 million.

Ordinary profit:

The initial forecast anticipates a ¥4,400 million decrease by recognizing as non-operating expenses the ¥440 million change in the time value of contingent consideration related to the acquisition of Curio Bioscience Inc., which was previously included in SG＆A expenses.

Net income attributable to owners of parent:

Recording an impairment loss of ¥3,870 million on contract manufacturing equipment and partially writing down deferred tax assets resulted in an estimated ¥9,000 million loss.

Analysis of Factors Affecting Operating Profit (Year-on-Year Comparison)



Consolidated Financial Forecast for the year ending March 31, 2026 (Revised)

(¥m)	FY2026 Forecast (Revised)	Y/Y	Comparison with May 13 forecast
Net sales	42,100	▲2,939 ▲6.5%	▲10,400 ▲19.8%
Reagents	29,731	▲2,263 ▲7.1%	▲7,371 ▲19.9%
Instruments	1,081	▲90 ▲7.7%	▲686 ▲38.8%
CDMO	8,245	+132 +1.6%	▲1,958 ▲19.2%
Gene Therapy	3,040	▲717 ▲19.1%	▲383 ▲11.2%
Gross Profit	21,891	▲4,175 ▲16.0%	▲8,133 ▲27.1%
Operating profit	▲4,000	▲6,263 -	▲6,500 -
R&D expenses	7,106	+208 +3.0%	▲576 ▲7.5%

Sales vs. Initial Forecast †

Reagents: Significant shortfall expected due to U.S. government research grant cuts, October government shutdown, China's economic downturn, and intensified competition with local companies (Spatial products were expected to grow significantly in the second half but are now projected to fall far short).

Instruments: Due to a decline in sales of single-cell analysis systems and other factors, performance is expected to fall short of the target

Contract Manufacturing for Regenerative Medicine Products : The market for regenerative medicine, cell therapy, and gene therapy has not grown as expected, and the significant impact of missed new orders is leading to an anticipated shortfall.

Contract Services for Genetic Analysis and Testing : The significant impact of reduced revenue from genome analysis services in the first half has led to a decrease compared to the forecast.

Gene Therapy: Although the decline in demand for RetroNectin® from major customers was anticipated, further expansion did not materialize, resulting in a decrease compared to the forecast.

† Announced on May 13, 2025.

Analysis of Factors Affecting Operating Profit (vs. May 13 Forecast)



Shareholder Returns



Dividends Policy

The Company considers returning profits to shareholders to be an important management issue, while paying attention to enhancing internal reserves in order to actively implement R&D activities. The basic policy is to return profits to shareholders based on a comprehensive consideration of our operating results and financial position. Beginning in FY 2024, its dividend policy aims for 35% of net income assumed, calculated without any extraordinary gains or losses in the consolidated financial statements.

Website "Shareholder Returns and Dividends" : https://www.takara-bio.co.jp/ja/ir/stock/dividend.html

Aiming to become a biologics development company continuing to create new modalities with the twin pillars of Research support and CDMO businesses



Takara Bio Group Long-Term Vision 2050

Expanding the scope of activities from Human Health to Planetary Health



This vision is Takara Bio Group's COMPASS for the future
Taking the biotechnological transformation in all industries as an opportunity to grow,
The Groupe is expanding the scope of its activities to not only the traditional medical and healthcare fields but also the fields that contribute to solving global social issues, while creating new businesses such as biomanufacturing, deepening the existing businesses and realizing a quantum leap growth by utilizing our core competence in DNA technologies including technologies to analyze ultra-low amounts of gene and cell products and technologies to produce high-performance, high-quality gene, protein and cell products in large quantities.

Forward-looking Statements

Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, decline in selling power of the Company's existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

For more Information：Public & Investor Relations Department
E-mail: bio-ir@takara-bio.co.jp

【Reference】

Reference Information

- Consolidated Financial Results (First Half)
- Consolidated Financial Results (Second Half Forecast)
- Consolidated Financial Forecast (Full-year Forecast [Revised])
- Net Sales by Category (First Half)
- Net Sales by Category (Second Half Forecast [Revised])
- Net Sales by Category (Full-year Forecast [Revised])
- Reagents Sales by Region (Full-year Forecast [Revised])
- Reagents Sales by Region (First Half & Second Half Forecast [Revised])
- Performance by Subsidiaries (First Half Actual & Full-year Forecast [Revised])
- Exchange Rate (Actual, Forecast)
- Gene Therapy Business: TBI-1301, NY-ESO-1・siTCR® gene therapy

【Reference】

Consolidated Financial Results (First Half)

(¥m)	FY2026 First Half	Y/Y		Comparison with initial forecast†	
		Change	Ratio	Change	Ratio
Net sales	18,794	▲963	▲4.9%	▲2,505	▲11.8%
Cost of sales	8,230	+917	+12.5%	▲684	▲7.7%
Gross profit	10,564	▲1,880	▲15.1%	▲1,820	▲14.7%
SG&A expenses	12,907	+878	+7.3%	▲927	▲6.7%
Operating profit	▲2,342	▲2,759	-	▲892	-
Ordinary profit	▲2,485	▲3,034	-	▲1,055	-
Net income attributable to owners of parent	▲6,911	▲7,424	-	▲5,591	-

FY2026: from Apr. 1, 2025 to Mar. 31, 2026
¥m: millions of yen

† Announced on May 13, 2025.

【Reference】

Consolidated Financial Forecast (Second Half) 【Revised 】

(¥m)	FY2026 Second Half	Y/Y		Comparison with initial forecast†	
		Change	Ratio	Change	Ratio
Net sales	23,305	▲1,976	▲7.8%	▲7,894	▲25.3%
Cost of sales	11,978	+319	+2.7%	▲1,581	▲11.7%
Gross profit	11,327	▲2,295	▲16.8%	▲6,313	▲35.8%
SG&A expenses	12,984	+1,208	+10.3%	▲706	▲5.2%
Operating profit	▲1,657	▲3,503	-	▲5,607	-
Ordinary profit	▲1,914	▲3,957	-	▲5,844	-
Net income attributable to owners of parent	▲2,088	▲2,617	-	▲4,708	-

† Announced on May 13, 2025.

【Reference】

Consolidated Financial Results (Full-year Forecast) 【Revised 】

(¥m)	FY2026 Full-Year forecast	Y/Y		Comparison with Initial forecast†	
		Change	Ratio	Change	Ratio
Net sales	42,100	▲2,939	▲6.5%	▲10,400	▲19.8%
Cost of sales	20,208	+1,236	+6.5%	+2,266	▲10.1%
Gross profit	21,891	▲4,175	▲16.0%	▲8,133	▲27.1%
SG&A expenses	25,891	+2,087	+8.8%	▲1,633	▲5.9%
Operating profit	▲4,000	▲6,263	—	▲6,500	—
Ordinary profit	▲4,400	▲6,992	—	▲6,900	—
Net income attributable to owners of parent	▲9,000	▲10,041	—	▲10,300	—

FY2026: from Apr. 1, 2025 to Mar. 31, 2026
¥m: millions of yen

† Announced on May 13, 2025.

【Reference】

Net Sales by Category (First Half)

(¥m)	FY2026 First Half	Y/Y		Comparison with initial forecast†	
		Change	Ratio	Change	Ratio
Reagents	14,272	▲1,131	▲7.4%	▲1,746	▲10.9%
Instruments	402	▲23	▲5.6%	▲292	▲42.1%
CDMO	2,546	271	+12.0%	▲477	▲15.8%
Regenerative medicine	1,622	658	+68.3%	+6	+0.4%
Gene analysis/testing	731	▲336	▲31.5%	▲481	▲39.7%
Others	192	▲49	▲20.6%	▲2	▲1.3%
Gene Therapy	1,573	▲78	▲4.7%	+10	+0.7%
Total net sales	18,794	▲963	▲4.9%	▲2,505	▲11.8%

† Announced on May 13, 2025.

【Reference】

Net Sales by Category (Second Half Forecast)【Revised】

(¥m)	FY2026 First Half	Y/Y		Comparison with initial forecast†	
		Change	Ratio	Change	Ratio
Reagents	15,459	▲1,130	▲6.8%	▲5,625	▲26.7%
Instruments	678	▲66	▲9.0%	▲394	▲36.7%
CDMO	5,699	▲139	▲2.4%	▲1,480	▲20.6%
Regenerative medicine	2,695	▲442	▲14.1%	▲1,405	▲34.3%
Gene analysis/testing	2,868	+348	+13.8%	+0	+0.0%
Others	135	▲45	▲25.0%	▲75	▲35.7%
Gene Therapy	1,466	▲639	▲30.3%	▲394	▲21.2%
Total net sales	23,305	▲1,976	▲7.8%	▲7,894	▲25.3%

† Announced on May 13, 2025.

【Reference】

Net Sales by Category (Full-year Forecast) [Revised]

(¥m)	FY2025 Full-Year forecast	Y/Y		Comparison with initial forecast†	
		Change	Ratio	Change	Ratio
Reagents	29,731	▲2,263	▲7.1%	▲7,371	▲19.9%
Instruments	1,081	▲90	▲7.7%	▲686	▲38.8%
CDMO	8,245	+132	+1.6%	▲1,958	▲19.2%
Regenerative medicine	4,318	+215	+5.2%	▲1,399	▲24.5%
Gene analysis/testing	3,600	+11	+0.3%	▲481	▲11.8%
Others	327	▲95	▲22.5%	▲77	▲19.2%
Gene Therapy	3,040	▲717	▲19.1%	▲383	▲11.2%
Total net sales	42,100	▲2,939	▲6.5%	▲10,400	▲19.8%

† Announced on May 13, 2025.

TaKaRa

【Reference】

Reagents Sales by Region (Full-year Forecast) [Revised]

	(¥m)	FY2026 Forecast	Y/Y			vs. Initial forecast†		
			Change	For exchange	Ratio (Exchange excluded)	Change	For exchange	Ratio (Exchange excluded)
Japan	H1	2,771	+73	0	+2.7%	▲ 381	0	▲12.1%
	H2	3,784	▲ 16	0	▲0.4%	▲ 496	0	▲11.6%
	Full	6,555	+57	0	+0.9%	▲ 877	0	▲11.8%
U.S.	H1	6,844	+63	▲ 182	+3.6%	▲ 701	▲ 27	▲8.9%
	H2	6,421	+323	▲ 204	+8.7%	▲ 2,751	▲ 116	▲28.7%
	Full	13,265	+386	▲ 386	+6.0%	▲ 3,452	▲ 143	▲19.8%
Europe	H1	1,756	+110	▲ 23	+8.1%	▲ 37	43	▲4.5%
	H2	2,033	+267	75	+10.8%	▲ 302	137	▲18.8%
	Full	3,789	+377	52	+9.5%	▲ 339	180	▲12.6%
China	H1	1,927	▲ 1,386	▲ 58	▲40.1%	▲ 432	22	▲19.3%
	H2	2,143	▲ 1,805	▲ 67	▲44.0%	▲ 1,835	17	▲46.5%
	Full	4,070	▲ 3,191	▲ 125	▲42.2%	▲ 2,267	39	▲36.4%
Korea	H1	572	▲ 22	▲ 46	+4.1%	▲ 133	▲ 26	▲15.2%
	H2	657	+78	▲ 26	+18.0%	▲ 162	▲ 20	▲17.3%
	Full	1,229	+56	▲ 72	+11.0%	▲ 295	▲ 46	▲16.3%
India	H1	398	+27	▲ 25	+14.3%	▲ 58	4	▲13.9%
	H2	422	+22	▲ 28	+12.4%	▲ 82	▲ 4	▲15.3%
	Full	820	+49	▲ 53	+13.3%	▲ 140	0	▲14.6%
Total	H1	14,272	▲ 1,133	▲ 335	▲5.2%	▲ 1,746	16	▲11.0%
	H2	15,459	▲ 1,130	▲ 249	▲5.3%	▲ 5,625	13	▲26.7%
	Full	29,731	▲ 2,263	▲ 584	▲5.2%	▲ 7,371	29	▲19.9%

† Announced on May 13, 2025.

TaKaRa

【Reference】

Reagents Sales by Region

(First Half & Second Half Forecast) [Revised]

	(¥m)	FY2026 Forecast	Y/Y			vs. Initial forecast†		
			Change	For exchange	Ratio (Exchange excluded)	Change	For exchange	Ratio (Exchange excluded)
H1	Japan	2,771	+73	0	+2.7%	▲ 381	0	▲12.1%
	U.S.	6,844	+63	▲ 182	+3.6%	▲ 701	▲ 27	▲8.9%
	Europe	1,756	+110	▲ 23	+8.1%	▲ 37	43	▲4.5%
	China	1,927	▲ 1,386	▲ 58	▲40.1%	▲ 432	22	▲19.2%
	Korea	572	▲ 22	▲ 46	+4.1%	▲ 133	▲ 26	▲15.2%
	India	398	+27	▲ 25	+14.3%	▲ 58	4	▲13.9%
	Total	14,272	▲ 1,133	▲ 335	▲5.2%	▲ 1,746	16	▲11.0%
H2	Japan	3,784	▲ 16	0	▲0.4%	▲ 496	0	▲11.6%
	U.S.	6,421	+323	▲ 204	+8.7%	▲ 2,751	▲ 116	▲28.7%
	Europe	2,033	+267	75	+10.8%	▲ 302	137	▲18.8%
	China	2,143	▲ 1,805	▲ 67	▲44.0%	▲ 1,835	17	▲46.5%
	Korea	657	+78	▲ 26	+18.0%	▲ 162	▲ 20	▲17.3%
	India	422	+22	▲ 28	+12.4%	▲ 82	▲ 4	▲15.3%
	Total	15,459	▲ 1,130	▲ 249	▲5.3%	▲ 5,625	13	▲26.7%
Full	Japan	6,555	+57	0	+0.9%	▲ 877	0	▲11.8%
	U.S.	13,265	+386	▲ 386	+6.0%	▲ 3,452	▲ 143	▲19.8%
	Europe	3,789	+377	52	+9.5%	▲ 339	180	▲12.6%
	China	4,070	▲ 3,191	▲ 125	▲42.2%	▲ 2,267	39	▲36.4%
	Korea	1,229	+56	▲ 72	+11.0%	▲ 295	▲ 46	▲16.3%
	India	820	+49	▲ 53	+13.3%	▲ 140	0	▲14.6%
	Total	29,731	▲ 2,263	▲ 584	▲5.2%	▲ 7,371	29	▲19.9%

† Announced on May 13, 2025.

【Reference】

Performance by Subsidiaries (Full-year Forecast)[Revised]

(¥m)	First Half Actual		Full-year Forecast (Revised)	
	Net sales	Operating profit	Net sales	Operating profit
Takara Bio (Non-consolidated)	9,801	▲2,002	24,261	▲2,387
Takara Bio Europe （consolidated）	2,405	24	4,813	6
Takara Biotechnology (Dalian)	1,483	▲39	3,141	▲136
Takara Biomedical (Beijing)	2,516	20	5,191	15
Takara Korea Biomedical	645	84	1,433	182
DSS Takara India	424	46	884	97
Takara Bio USA	8,486	▲478	16,314	▲1,247

【Reference】

Exchange Rate (Actual, Forecast)

(Unit: Yen)	FY2025 Semi-annual Actual	FY2026 Semi-annual Actual	FY2025 Full-year Actual	FY2026 Full-year Forecast
US dollar	152.36	148.41	151.69	147.40
Euro	164.69	162.25	164.04	166.60
Yuan	21.06	20.44	21.03	20.40
100 Won	11.27	10.42	11.12	10.50
Rupee	1.83	1.72	1.81	1.70
Pound	192.78	192.61	193.83	194.80

【Reference】

Gene Therapy Business: Promote the Development of TBI-1301, NY-ESO-1・siTCR® gene therapy product

NY-ESO-1・siTCR® gene therapy TBI-1301 recognizes and attacks cancer cells



Overview of Verification Testing

Title	Multicenter Study of TBI-1301 (INN: mipetresgene autoleucel; Mip-cel) for NY-ESO-1 Antigen-Positive Synovial Sarcoma
Phase	Phase III
Indication	Unresectable advanced or recurrent synovial sarcoma
Design	Non-controlled, multicenter
Enrollment	5 patients

Clinical Trial Information :
Japanese jRCT No. : jRCT2073250089
English ClinicalTrials.gov No : NCT07174427